Bedfont® will present its NObreath® FeNO technology at the American Thoracic Society conference, showing how it helps clinicians measure airway inflammation to improve asthma care.
Getting a clear picture of what’s happening in the airways during asthma is easier than ever, thanks to new advances in breath analysis. Bedfont® Scientific Ltd., with almost 50 years of experience in breath analysis, is preparing to introduce its NObreath® device to respiratory experts at a major medical event in Florida next year.
What Awaits at This Year’s Key Gathering
The American Thoracic Society International Conference will take place from May 15-20, 2026, at the Orange County Convention Center in Orlando, Florida. This major event brings together over 15,000 specialists in pulmonary, critical care, and sleep medicine. It’s a hub for sharing new research and discussing progress in patient care.
Bedfont® will be at booth 1236, where they’ll showcase their FeNO (Fractional exhaled Nitric Oxide) monitor, together with their US distributor coVita™. The conference offers innovators a direct line to clinicians, giving them a chance to present the latest tools in respiratory medicine.
Events like ATS often play a key role in bringing new technologies into everyday clinics and hospitals. Attendees get a close look at how these advances can shape clinical practice and improve outcomes for patients.
Behind the Scenes of a Simple Breath Test
The NObreath® device gives doctors a quick, non-invasive way to measure airway inflammation with a simple breath test. Since inflammation is a main factor in asthma, this tool has given doctors valuable, objective data for more than 15 years.
Here’s how it works: patients breathe into the handheld device, which measures nitric oxide levels in the breath. Higher readings mean more inflammation. The test only takes a few minutes and gives important information for managing asthma.
With these results, doctors can make better decisions about medication. Instead of relying only on symptoms, they can see if a patient’s inflammation is under control. This leads to more personalized asthma treatment.
Where FeNO Testing Fits Into Modern Care
FeNO testing gives a direct look at airway inflammation, which can sometimes go unnoticed with regular symptom checks or lung function tests. There are times when inflammation is present without clear symptoms. NObreath® helps spot these cases, allowing for earlier action and better long-term management.
This technology connects current knowledge with the future of care. By providing objective data, it helps shape treatment plans tailored to each person, moving asthma care toward a more personalized approach.
Inside Insights from the Conference Floor
Jason Smith, CEO, Bedfont®, shared his thoughts on the importance of the conference: “We’re excited to be part of ATS this year and to bring our expert team together on the stand to engage with the global respiratory community. We invite attendees to come and speak with us, experience our technology firsthand, and explore how we can work together. ATS provides an important platform for us to showcase the NObreath® and its impact in respiratory care.”
Bedfont® will have team members available throughout the conference to demonstrate the device and answer questions.
Carol Stonham MBE, a respiratory expert and Medical Advisory Board Member, will also be at booth 1236. As the Children and Young People Asthma Clinical Lead at Gloucestershire ICB, she brings a wealth of clinical experience. Stonham will discuss how FeNO testing is used in practice and highlight new opportunities for asthma care.
Stonham is scheduled to deliver a talk at Innovation Hub 3 on Sunday, May 17, at 1:15 pm EDT. She will cover the role of FeNO in clinical settings and discuss recent developments in the field.
Looking Toward a New Standard in Asthma Care
Improving asthma management directly affects millions of people worldwide. Devices like NObreath® support more accurate and effective treatment. By tracking inflammation levels, doctors can help prevent asthma attacks and improve patients’ quality of life.
Bedfont’s long-standing focus on breath analysis is clear from their nearly 50-year history. Their devices are now used in healthcare settings globally, helping to advance the future of respiratory care.
Anyone interested in learning more about NObreath® can visit Bedfont’s team at booth 1236 from May 17 to 19, where demonstrations and answers to questions about FeNO in asthma care will be available.
As technology moves forward, personalized monitoring may soon become a regular part of managing asthma and other respiratory diseases. Events like ATS help bring these advances into daily clinical practice, benefiting both patients and healthcare professionals.
Source: News Medical